Navigation Links
Medarex to Present at the UBS Global Life Sciences Conference
Date:9/17/2008

PRINCETON, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the UBS Global Life Sciences Conference at 4:30 p.m. Eastern Time on Monday, September 22, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at http://www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
2. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
3. Medarex Announces July 10 Live Webcast of R&D Day Event
4. Medarex to Present at the Jefferies Second Annual Healthcare Conference
5. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
6. Medarex to Present at the Bank of America 2008 Healthcare Conference
7. Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
9. Medarex to Receive Milestone Payment from Novo Nordisk
10. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Toronto, Canada (PRWEB) , ... May 23, 2017 ... ... of Firmex FileSend, a cloud-based file transfer solution that makes it easy for ... firewall without having to worry about cumbersome FTP software or email file size ...
(Date:5/23/2017)... Ca (PRWEB) , ... May ... ... (PSCs) offer an unlimited source of human cardiovascular cells for research and ... differentiation methods makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). ...
(Date:5/23/2017)... ... 2017 , ... NetDimensions has been ranked as a Leader ... Corporate Learning, 2017. , Aragon Research defines Leaders as organizations who possess comprehensive ... those strategies. NetDimensions’ ranking as a Leader due to its strengths in: , ...
(Date:5/23/2017)... PARK, CA (PRWEB) , ... May 23, 2017 , ... ... the publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic ... is the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):